U.S. flag

An official website of the United States government

NM_000527.5(LDLR):c.2041T>G (p.Cys681Gly) AND Familial hypercholesterolemia

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Sep 26, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002229693.6

Allele description [Variation Report for NM_000527.5(LDLR):c.2041T>G (p.Cys681Gly)]

NM_000527.5(LDLR):c.2041T>G (p.Cys681Gly)

Gene:
LDLR:low density lipoprotein receptor [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
19p13.2
Genomic location:
Preferred name:
NM_000527.5(LDLR):c.2041T>G (p.Cys681Gly)
HGVS:
  • NC_000019.10:g.11120423T>G
  • NG_009060.1:g.36043T>G
  • NM_000527.5:c.2041T>GMANE SELECT
  • NM_001195798.2:c.2041T>G
  • NM_001195799.2:c.1918T>G
  • NM_001195800.2:c.1537T>G
  • NM_001195803.2:c.1606+190T>G
  • NP_000518.1:p.Cys681Gly
  • NP_000518.1:p.Cys681Gly
  • NP_001182727.1:p.Cys681Gly
  • NP_001182728.1:p.Cys640Gly
  • NP_001182729.1:p.Cys513Gly
  • LRG_274t1:c.2041T>G
  • LRG_274:g.36043T>G
  • LRG_274p1:p.Cys681Gly
  • NC_000019.9:g.11231099T>G
  • NM_000527.4:c.2041T>G
  • c.2041T>G
Protein change:
C513G
Links:
LDLR-LOVD, British Heart Foundation: LDLR_000275; dbSNP: rs879255118
NCBI 1000 Genomes Browser:
rs879255118
Molecular consequence:
  • NM_001195803.2:c.1606+190T>G - intron variant - [Sequence Ontology: SO:0001627]
  • NM_000527.5:c.2041T>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195798.2:c.2041T>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195799.2:c.1918T>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195800.2:c.1537T>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Familial hypercholesterolemia
Identifiers:
MONDO: MONDO:0005439; MedGen: C0020445; OMIM: PS143890

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000544651Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Sep 26, 2023)
germlineclinical testing

PubMed (9)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

LDLR promoter variant and exon 14 mutation on the same chromosome are associated with an unusually severe FH phenotype and treatment resistance.

Snozek CL, Lagerstedt SA, Khoo TK, Rubenfire M, Isley WL, Train LJ, Baudhuin LM.

Eur J Hum Genet. 2009 Jan;17(1):85-90. doi: 10.1038/ejhg.2008.138. Epub 2008 Jul 23.

PubMed [citation]
PMID:
18648394
PMCID:
PMC2985960

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia.

Defesche JC, Stefanutti C, Langslet G, Hopkins PN, Seiz W, Baccara-Dinet MT, Hamon SC, Banerjee P, Kastelein JJP.

J Clin Lipidol. 2017 Nov - Dec;11(6):1338-1346.e7. doi: 10.1016/j.jacl.2017.08.016. Epub 2017 Sep 4. Erratum in: J Clin Lipidol. 2020 Sep - Oct;14(5):742. doi: 10.1016/j.jacl.2020.09.010.

PubMed [citation]
PMID:
28964736
See all PubMed Citations (9)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV000544651.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (9)

Description

ClinVar contains an entry for this variant (Variation ID: 252185). This sequence change replaces cysteine, which is neutral and slightly polar, with glycine, which is neutral and non-polar, at codon 681 of the LDLR protein (p.Cys681Gly). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with familial hypercholesterolemia or elevated low-density lipoprotein cholesterol (PMID: 18648394, 28964736; Invitae). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LDLR protein function. This variant affects a cysteine residue located within an LDLRA or epidermal-growth-factor (EGF)-like domains of the LDLR protein. Cysteine residues in these domains have been shown to be involved in the formation of disulfide bridges, which are critical for protein structure and stability (PMID: 7548065, 7603991, 7979249). In addition, missense substitutions within the LDLRA and EGF-like domains affecting cysteine residues are overrepresented among patients with hypercholesterolemia (PMID: 18325082). This variant disrupts the p.Cys681 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been observed in individuals with LDLR-related conditions (PMID: 9544745, 16092059), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024